DSIP: Research & Studies
Scientific evidence, clinical trials, and research findings
๐TL;DR
- โข5 clinical studies cited
- โขOverall evidence level: low
- โข5 research gaps identified
Research Studies
The delta sleep inducing peptide (DSIP). Comparative properties of the original and synthetic nonapeptide
Schoenenberger GA, Maier PF, Tobler HJ, et al. (1977) โข Experientia
Original characterization of DSIP comparing the naturally isolated peptide with its synthetic counterpart, confirming identical sleep-inducing properties.
Key Findings
- Synthetic DSIP reproduced the sleep-inducing properties of natural extract
- Confirmed nonapeptide sequence
- Established delta-wave sleep promotion in rabbits
Limitations: Initial characterization in rabbits only
Delta sleep-inducing peptide (DSIP): a still unresolved riddle
Kastin AJ, Zadina JE, Banks WA, et al. (2006) โข Journal of Neurochemistry
Comprehensive review examining the inconsistencies and unresolved questions in DSIP research, including its mechanism of action and clinical relevance.
Key Findings
- DSIP mechanism remains incompletely understood
- No specific receptor identified
- Pleiotropic effects extend beyond sleep modulation
Limitations: Review article; no new experimental data
Effects of delta sleep-inducing peptide on sleep of chronic insomniac patients. A double-blind study
Schneider-Helmert D, Schoenenberger GA (1983) โข Neuropsychobiology
Double-blind study examining DSIP effects in chronic insomnia patients, finding improvements in sleep efficiency and latency.
Key Findings
- Higher sleep efficiency with DSIP compared to placebo
- Shorter sleep latency reported
- Build-up effect observed with repeated administrations
Limitations: Small sample size; short treatment duration
A clinical trial with DSIP
Schneider-Helmert D (1984) โข European Neurology
Clinical evaluation of DSIP in patients with insomnia, assessing both objective and subjective sleep parameters.
Key Findings
- Improvements in subjective sleep quality
- Some patients showed sustained benefit after treatment cessation
- Generally well-tolerated
Limitations: Small sample; heterogeneous patient population
Acute and delayed effects of DSIP on human sleep behavior
Schneider-Helmert D, Schoenenberger GA (1983) โข International Journal of Peptides and Protein Research
Examined immediate and delayed sleep effects of DSIP administration in humans, finding normalization of sleep structure.
Key Findings
- Two administrations showed improvement of sleep
- Four administrations led to normalization of sleep structure
- Effects persisted beyond the treatment period
Limitations: Small study; limited follow-up duration
Unlock full research citations
Free access to all clinical studies, citations, and evidence summaries.
150+ peptide profiles ยท 30+ comparisons ยท 18 research tools
Community Experience Data
See how community outcomes align with (or diverge from) the research findings above.
Based on 80+ community reports
View community protocolsExplore research gaps across all peptides โ | View clinical trial pipeline โ
๐Research Gaps & Future Directions
- โขNo large-scale placebo-controlled clinical trials
- โขSpecific receptor not identified after decades of research
- โขMechanism of action remains incompletely characterized
- โขOptimal dosing regimen not established
- โขLong-term efficacy and safety data lacking
Research Overview#
DSIP has been studied for over four decades since its discovery in 1977. The research spans animal sleep studies, human clinical trials for insomnia, investigations of neuroendocrine effects, and explorations of analgesic and stress-modulating properties. Despite this extensive body of work, DSIP remains, as one review noted, "a still unresolved riddle" due to inconsistencies in the literature and the failure to identify a specific receptor.
Key Animal Studies#
Sleep Induction#
The original experiments by Schoenenberger and colleagues demonstrated that dialysate from the cerebral venous blood of rabbits in electrically induced sleep, when infused into recipient rabbits, produced delta-wave sleep. The active component was isolated and identified as the nonapeptide DSIP. Synthetic DSIP reproduced these effects, confirming the sequence assignment.
Subsequent animal studies extended these findings to mice, rats, and cats, with DSIP consistently promoting slow-wave sleep when administered centrally. The sleep-promoting effect was characterized by increased EEG delta power and extended duration of slow-wave sleep episodes.
Analgesic Effects#
Animal studies have revealed analgesic properties of DSIP beyond its sleep effects. Intracerebroventricular and intracisternal administration produced antinociception in mice, with effects measured in standard pain models including the hot-plate and tail-flick tests. The analgesic mechanism appears to be distinct from opioid pathways, as naloxone only partially attenuated the effects.
Anticonvulsant Activity#
In rats with metaphit-induced epilepsy, DSIP significantly decreased both the incidence and duration of seizures. This anticonvulsant activity suggests that DSIP modulates neuronal excitability through mechanisms that may be related to its effects on GABAergic neurotransmission.
Human Clinical Studies#
Double-Blind Insomnia Trial#
Schneider-Helmert and Schoenenberger (1983) conducted a double-blind study in chronic insomnia patients using DSIP (25 nmol/kg body weight intravenously). The study found higher sleep efficiency and shorter sleep latency with DSIP compared to placebo. However, the investigators concluded that short-term treatment of chronic insomnia with DSIP was "not likely to be of major therapeutic benefit," suggesting that longer treatment courses might be necessary.
Repeated Administration Studies#
A series of studies examining repeated DSIP administrations in insomnia patients (typically 10 injections over 10 days) reported more promising results. In one open study, 7 patients with severe insomnia were treated with a series of 10 DSIP injections, and in all but 1 case, sleep was normalized for follow-up periods of 3 to 7 months. The observation of persistent effects after treatment cessation suggested a normalizing effect on sleep regulation rather than a direct sedative action.
Alcohol and Opioid Withdrawal#
Preliminary studies have explored DSIP as an adjunct in substance withdrawal management. The rationale is based on DSIP's sleep-promoting, stress-reducing, and cortisol-suppressing properties. Results have been encouraging but come from small, uncontrolled studies that cannot establish efficacy.
Evidence Quality Assessment#
The overall evidence quality for DSIP is low. While the preclinical data consistently demonstrate sleep-promoting and neuromodulatory effects, the human clinical evidence is limited to small studies with heterogeneous designs, patient populations, and outcome measures. The failure to identify a specific receptor or fully elucidate the mechanism of action is a significant limitation. Many of the human studies were conducted in the 1980s, and contemporary large-scale trials with modern sleep assessment methodology have not been performed.
Ongoing Questions#
The fundamental question of whether DSIP is truly a physiological sleep-regulating peptide or merely a pharmacological agent that happens to promote sleep when administered exogenously remains debated. The circadian variation of endogenous DSIP levels supports a physiological role, but the absence of a specific receptor and the inconsistency of clinical results leave this question open.
Related Reading#
Where to Find DSIP
Research-grade suppliers verified by our scoring methodology.
Frequently Asked Questions About DSIP
Explore Further
Medical Disclaimer
This website is for educational and informational purposes only. The information provided is not intended to diagnose, treat, cure, or prevent any disease. Always consult with a qualified healthcare professional before using any peptide or supplement.